
|Articles|April 16, 2007
Valve risk leads to withdrawal of pergolide (Permax, Valiant)
Two high-quality reports in the New England Journal of Medicine confirming the risk of valvulopathy with the use of pergolide (Permax, Valiant) have led the FDA to remove the drug from the U.S. market. Two generic forms of the drug, made by Teva and Par Pharmaceuticals, will also be withdrawn.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Pneumococcal Vaccination at 50 Years Old Can Improve Outcomes
5





























































